|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Trial E2100: Bevacizumab with paclitaxel as first-line treatment of metastatic disease |
|
|
| Track 3 |
Progression-free survival as an endpoint in metastatic disease trials |
|
|
| Track 4 |
Mechanism of action of bevacizumab |
|
|
| Track 5 |
Integration of bevacizumab into treatment in the metastatic setting |
|
|
| Track 6 |
Clinical use of nanoparticle albumin-bound (nab) paclitaxel |
|
|
| Track 7 |
Contraindications for utilization of bevacizumab |
|
|
| Track 8 |
Future directions in clinical trials of bevacizumab |
|
|
| Track 9 |
Impact of adjuvant trastuzumab data on future trials of adjuvant chemotherapy |
|
|
| Track 10 |
Combined analysis of NSABP-B-31/NCCTG-N9831 trials of adjuvant trastuzumab |
|
|
| Track 11 |
Results of the HERA adjuvant trastuzumab trial |
|
|
| Track 12 |
Cardiac toxicity data from clinical trials of adjuvant trastuzumab |
|
|
| Track 13 |
Cardiac safety in BCIRG 006 |
|
|
| Track 14 |
Magnitude of benefit of anthracyclines in patients with HER2-positive disease |
|
|
| Track 15 |
Impact of adjuvant chemotherapy on patients with ER-positive disease |
|
|
| Track 16 |
Clinical implications of the adjuvant trastuzumab trial results |
|
|
| Track 17 |
Clinical use of delayed adjuvant trastuzumab |
|
|
| Track 18 |
Importance of reliable and accurate HER2 testing for treatment decisions |
|
|
| Track 19 |
Future adjuvant trials in patients with HER2-positive tumors |
|
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Integrating aromatase inhibitors into adjuvant therapy of women with ER-positive disease |
|
|
| Track 3 |
Importance of quality control in hormone receptor testing |
|
|
| Track 4 |
Approach to adjuvant endocrine therapy in postmenopausal women |
|
|
| Track 5 |
Management of hormone receptor-positive disease in premenopausal and perimenopausal women |
|
|
| Track 6 |
Aromatase inhibitors after five years of tamoxifen in postmenopausal women |
|
|
| Track 7 |
Perspective on emerging data on cardiac events in trials of adjuvant aromatase inhibitors |
|
|
| Track 8 |
Selection of aromatase inhibitors at different timepoints in the adjuvant setting |
|
|
| Track 9 |
Approach to and sequencing of therapy of ER-positive metastatic disease |
|
|
| Track 10 |
Clinical experience with fulvestrant |
|
|
| Track 11 |
Approach to therapy in patients with HER2-positive metastatic disease |
|
|
| Track 12 |
Continuation of trastuzumab beyond disease progression |
|
|
| Track 13 |
Future directions in adjuvant trastuzumab clinical trials |
|
|
| Track 14 |
Implications of accurate HER2 testing |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Background and rationale for
development of the Oncotype DX™ assay |
|
|
| Track 3 |
Oncotype DX assay to predict
prognosis for patients with early
breast cancer |
|
|
| Track 4 |
Utilization of the Oncotype DX
assay in clinical practice |
|
|
| Track 5 |
Perspective on the economics of
cancer treatment |
|
|
| Track 6 |
Recurrence score as a predictor
of response to therapy |
|
|
| Track 7 |
Integration of Oncotype DX assay
into clinical practice guidelines |
|
|
| Track 8 |
Results of NSABP-B-32 sentinel
node trial |
|
|
| Track 9 |
Sentinel lymph node biopsy:
Clinical issues in utilization |
|
|
| Track 10 |
Clinical use of adjuvant aromatase
inhibitors in postmenopausal
women |
|
|
| Track 11 |
Planned NSABP trial evaluating
optimal duration of aromatase
inhibitors |
|
|
| Track 12 |
Aromatase inhibitors for
chemoprevention and treatment
of DCIS |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Dose of capecitabine |
|
|
| Track 3 |
Integration of bevacizumab into treatment in the metastatic setting |
|
|
| Track 4 |
Adjuvant endocrine therapy for premenopausal women |
|
|
| Track 5 |
Switching from tamoxifen to an aromatase inhibitor after
chemotherapy-induced menopause |
|
|
| Track 6 |
Integration of adjuvant trastuzumab into clinical practice |
|
|
| Track 7 |
Use of fulvestrant in ER-positive metastatic disease |
|
|
|
|
